Abstract 305P
Background
There is no evidence of effective follow-up for the detection of recurrent head and neck cancer (HNC). There are few reports on the frequency of relapse of platinum-resistant HNC in clinical practice. Local recurrence is often seen during the first two years during which follow-up computed tomography (CT)/magnetic resonance imaging is recommended. The occurrence rate of second cancer (SC) has been reported to be 14.5%.
Methods
We conducted a retrospective analysis to evaluate the clinical course in 374 patients with head and neck squamous cell carcinoma who underwent definitive treatment at our institute between January 1998 and November 2018. The observation period was until January 2019.
Results
Recurrence and/or metastasis of HNC (R/M HNC) and SC were seen in 128 and 34 patients, respectively. The sites of R/M HNC were the hypopharynx, oral cavity, and larynx in 30.5%, 21.9%, and 19.5% of the patients, respectively. The sites of SC were the larynx, hypopharynx, and oropharynx in 38.2%, 26.5%, and 20.6% of the patients, respectively. At the diagnosis of relapse of new cancer, 50% of patients with R/M HNC and 44.1% of those with SC were symptomatic. The most common symptom was pain, while other symptoms were swelling, loss of appetite, hoarseness, dysphagia, dyspnea, cough, and bleeding. The modality of detection of recurrence was highest with CT (60.2%), followed by endoscopy (14.1%) and medical examination (14.1%). The median time to recurrence was 6.9 (range, 0 − 141.8) months, with 75% of recurrences occurring within one year. Furthermore, 4.8% of the recurrences occurred after five years. Platinum-resistant relapse accounted for 26.6% of all patients with R/M HNC and 58.6% of the relapses occurred within six months. The median time to recurrence was 35.5 (range, 1.5 − 240.9) months, with 35.3% of the recurrences occurring after five years.
Conclusions
In clinical practice, it is important to note the timing of rescue treatment during the follow-up period, focusing on imaging and medical examinations and confirming the symptoms within one year of treatment for HNC. During the long-term follow-up, observation for suspected development of SC is necessary.
Clinical trial identification
.
Editorial acknowledgement
.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract